SevenBridge Financial Group LLC Purchases 2,520 Shares of Zimmer Biomet Holdings, Inc. (ZBH)

SevenBridge Financial Group LLC lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 933.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,790 shares of the medical equipment provider’s stock after acquiring an additional 2,520 shares during the quarter. SevenBridge Financial Group LLC’s holdings in Zimmer Biomet were worth $327,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ZBH. Ingalls & Snyder LLC grew its stake in Zimmer Biomet by 2.6% in the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after purchasing an additional 507 shares during the last quarter. Koch Industries Inc. grew its stake in Zimmer Biomet by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after purchasing an additional 1,038,674 shares during the last quarter. Jensen Investment Management Inc. grew its stake in Zimmer Biomet by 24.2% in the second quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock valued at $751,000 after purchasing an additional 1,140 shares during the last quarter. Andra AP fonden grew its stake in Zimmer Biomet by 15.8% in the second quarter. Andra AP fonden now owns 21,300 shares of the medical equipment provider’s stock valued at $2,735,000 after purchasing an additional 2,900 shares during the last quarter. Finally, Commerce Bank grew its stake in Zimmer Biomet by 1.5% in the second quarter. Commerce Bank now owns 218,171 shares of the medical equipment provider’s stock valued at $28,013,000 after purchasing an additional 3,142 shares during the last quarter. Hedge funds and other institutional investors own 86.24% of the company’s stock.

Several equities analysts have issued reports on ZBH shares. Jefferies Group reiterated a “buy” rating and issued a $136.00 target price on shares of Zimmer Biomet in a research note on Friday, November 3rd. Gabelli initiated coverage on Zimmer Biomet in a research note on Thursday, August 24th. They issued a “buy” rating and a $142.00 target price on the stock. Oppenheimer set a $137.00 price target on Zimmer Biomet and gave the stock a “buy” rating in a research note on Monday, August 14th. SunTrust Banks set a $136.00 price target on Zimmer Biomet and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Finally, Edward Jones upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Thursday, November 9th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $133.71.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded down $2.53 during midday trading on Monday, reaching $114.57. The company had a trading volume of 1,487,900 shares, compared to its average volume of 1,358,791. The stock has a market capitalization of $23,197.34, a price-to-earnings ratio of 14.20, a P/E/G ratio of 1.78 and a beta of 1.15. Zimmer Biomet Holdings, Inc. has a 52-week low of $99.59 and a 52-week high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. Zimmer Biomet’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.79 EPS. sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/04/sevenbridge-financial-group-llc-purchases-2520-shares-of-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit